Deep Transcranial Magnetic Stimulation for Tobacco Cessation in Adults With Opioid Use Disorder (NCT07770555)
A Pilot Trial of Deep Transcranial Magnetic Stimulation (Deep TMS) for Tobacco Cessation in Patients With Opioid Use Disorder (OUD) Receiving Medications for Opioid Use Disorder (MOUD)
🩺 Plain-English Summary (8th-Grade Level)
This pilot study will evaluate the use of deep transcranial magnetic stimulation (Deep TMS) to help adults with opioid use disorder (OUD) who are receiving medications for opioid use disorder (MOUD) such as buprenorphine or methadone and who continue to smoke cigarettes and want to quit. Deep TMS is a noninvasive form of brain stimulation that uses magnetic pulses. The BrainsWay Deep TMS System is cleared by the U.S. Food and Drug Administration (FDA) for smoking cessation. This study will use the H4 coil smoking-cessation protocol in people with OUD receiving MOUD. Approximately 12 participants will take part and all participants will receive active Deep TMS. There is no sham or placebo group and no random assignment. Participants may receive up to 18 Deep TMS sessions over 6 weeks: five sessions per week during the first 3 weeks, followed by one session per week during Weeks 4 through 6. Participants will return for a follow-up visit at Week 10. The main purpose of the study is to learn whether this Deep TMS approach is safe, tolerable and feasible for people with OUD receiving MOUD and to estimate how many participants are able to remain smoke-free from Week 6 through Week 10. The study will also look for early changes in tobacco craving, opioid craving, continuation of MOUD, mood and anxiety symptoms, pain, heart rate variability, and participants' experiences with the treatment. The findings will be used to help plan a larger future study.
Who can join: Review the eligibility criteria below.
Location: UPMC Presbyterian — Pittsburgh, Pennsylvania
Age range: 22 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- UPMC Presbyterian — Pittsburgh, Pennsylvania
- University of Pittsburgh Medical Center (UPMC) Mercy - Internal Medicine Recovery Engagement Program (IM-REP) — Pittsburgh, Pennsylvania
📞 Contact the Study Coordinator
Phone: (412) 692-4473
Email: roypj@upmc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Opioid Use Disorder
- Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder — Atlantic City, New Jersey
- The Emergency Department Longitudinal Integrated Care — Seattle, Washington
- Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT — La Jolla, California
- Extended-release Buprenorphine as a Novel Low-dose Induction Strategy — Boston, Massachusetts
- Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial — Ann Arbor, Michigan
- Telemedicine XR-B for Individuals in Jail — Cumberland, Maryland
Explore by condition: All Opioid Use Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.